Understanding GRP78 and Lung Scarring in Pulmonary Fibrosis
Role of Chaperone GRP78 and Mitochondrial Dysfunction in ER Stress-Mediated Pulmonary Fibrosis
This research explores how a protein called GRP78 and issues with cell energy production contribute to the lung scarring seen in Idiopathic Pulmonary Fibrosis, a serious lung condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern California NIH-funded |
| Lab location | 1 site (Los Angeles, UNITED STATES) |
| Project ID | NIH-10995313 on NIH RePORTER |
What this research studies
Idiopathic Pulmonary Fibrosis (IPF) is a challenging lung disease where scar tissue builds up, especially as people get older. We believe that certain lung cells, called alveolar epithelial cells, become damaged when they lose a protective protein named GRP78, which helps keep cells healthy. This damage can also affect how cells produce energy, leading to an aging effect in these lung cells and ultimately causing the scarring. By understanding these processes, we hope to uncover new ways to help patients with IPF.
Who could benefit from this research
Good fit: Patients with Idiopathic Pulmonary Fibrosis, particularly those experiencing age-related progression of the disease, are the focus of this research.
Not a fit: Patients without Idiopathic Pulmonary Fibrosis or other forms of lung scarring would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to the development of more effective treatments for Idiopathic Pulmonary Fibrosis by targeting the specific cellular problems that cause lung scarring.
How similar studies have performed: Previous findings suggest that problems with GRP78 and cell stress are involved in IPF, and this research builds upon that knowledge to explore new molecular mechanisms.
Where this research is happening
Los Angeles, UNITED STATES
- University of Southern California — Los Angeles, United States (Active)
Researchers
- Principal investigator: Zhou, Beiyun — University of Southern California
- Study coordinator: Zhou, Beiyun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.